
Contents

Prefacev

Contents of Volume I xiii

Contributors xvii

PART I. INTRODUCTION

1 Molecular and Genetic Aspects of Lung Cancer
William N. Rom and Kam-Meng Tchou-Wong 3

PART II. DETECTION OF ALTERED TUMOR MARKERS IN CLINICAL SAMPLES
FOR DIAGNOSIS AND PROGNOSIS

A. MOLECULAR METHODS FOR PROGNOSTIC DETECTION OF ALTERED TUMOR
MARKERS: CLINICAL IMPLICATIONS

2 Molecular Alterations in Lung Cancer: *Impact on Prognosis*
Takashi Kijima, Gautam Maulik, and Ravi Salgia 29

3 Cellular Predictive Factors of Drug Resistance
in Non-Small Cell Lung Carcinomas
Manfred Volm, Reet Koomägi, and Werner Rittgen 39

4 Clinical Implications of p53 Mutations in Lung Cancer
Barbara G. Campling and Wafik S. El-Deiry 53

5 An Epidemiologic and Clinicopathologic Overview
of AIDS-Associated Pulmonary Kaposi's Sarcoma
David M. Aboulafia 79

6 Myeloperoxidase Promoter Region Polymorphism
and Lung Cancer Risk
Xifeng Wu, Matthew B. Schabath, and Margaret R. Spitz 121

7 Clinical Utility of Tumor Markers in the Management
of Non-Small Cell Lung Cancer
Dennis E. Niewoehner and Jeffrey B. Rubins 135

<i>B. MOLECULAR METHODS FOR PROGNOSTIC DETECTION OF ALTERED LUNG TUMOR MARKERS IN CLINICAL SAMPLES</i>	
<i>I. DNA-Based Analysis</i>	
8	Detection of Chromosomal Aberrations in Lung Tissue and Peripheral Blood Lymphocytes Using Interphase Fluorescence <i>In Situ</i> Hybridization (FISH) Randa A. El-Zein and Sherif Z. Abdel-Rahman 145
9	<i>In Situ</i> Analysis of Telomerase RNA Gene Expression as a Marker for Tumor Progression W. Nicol Keith 163
10	A High-Throughput Methodology for Identifying Molecular Targets Overexpressed in Lung Cancers Tongtong Wang and Steven G. Reed 177
11	Expression Profiling of Lung Cancer Based on Suppression Subtraction Hybridization (SSH) Simone Petersen and Iver Petersen 189
12	Comparative Genomic Hybridization of Human Lung Cancer Iver Petersen 209
13	Sensitive Assays for Detection of Lung Cancer: <i>Molecular Markers in Blood Samples</i> Marcia V. Fournier, Katherine J. Martin, Edgard Graner, and Arthur B. Pardee 239
14	Fluorescent Microsatellite Analysis in Bronchial Lavage as a Potential Diagnostic Tool for Lung Cancer John K. Field and Triantafillos Liloglou 251
15	Southern Blotting of Genomic DNA from Lung and Its Tumors: <i>Application to Analysis of Allele Loss on Chromosome 11p15.5</i> Diana M. Pitterle and Gerold Bepler 263
16	Assessment of Insulin-Like Growth Factors and Mutagen Sensitivity as Predictors of Lung Cancer Risk Xifeng Wu, He Yu, Nimisha Makan, and Margaret R. Spitz 279
<i>II. PCR-Based Analyses</i>	
17	Comparative Multiplex PCR and Allele-Specific Expression Analysis in Human Lung Cancer: <i>Tools to Facilitate Target Identification</i> Jim Heighway, Daniel Betticher, Teresa Knapp, and Paul Hoban 291
18	Detection of K-ras Point Mutations in Sputum from Patients with Adenocarcinoma of the Lung by Point-EXACCT Veerle A. M. C. Somers and Frederick B. J. M. Thunnissen 305

19	Detection of K-ras and p53 Mutations by "Mutant-Enriched" PCR-RFLP Marcus Schuermann	325
20	Detection of Small Cell Lung Cancer by RT-PCR for Neuropeptides, Neuropeptide Receptors, or a Splice Variant of the Neuron Restrictive Silencer Factor Judy M. Coulson, Samreen I. Ahmed, John P. Quinn, and Penella J. Woll	335
<i>III. Immunohistochemical Analyses</i>		
21	Utilization of Thyroid Transcription Factor-1 Immunostaining in the Diagnosis of Lung Tumors Nelson G. Ordóñez	355
22	Molecular Biologic Substaining of Stage I NSCLC Through Immunohistochemistry Performed on Formalin-Fixed, Paraffin-Embedded Tissue Mary-Beth Moore Joshi, Thomas A. D'Amico, and David H. Harpole, Jr.	369
23	A Sensitive Immunofluorescence Assay for Detection of p53 Protein in the Sputum Zumei Feng, Defa Tian, and Radoslav Goldman	389
24	SPR1: <i>An Early Molecular Marker for Bronchial Carcinogenesis</i> Derick Lau, Linlang Guo, Andrew Chan, and Reen Wu	397
25	Determination of Biological Parameters on Fine-Needle Aspirates from Non-Small Cell Lung Cancer Cecilia Bozzetti, Annamaria Guazzi, Rita Nizzoli, Nadia Naldi, Vittorio Franciosi, and Stefano Cascinu	405
<i>IV. Imaging Analysis</i>		
26	Detection and Analysis of Lung Cancer Cells from Body Fluids Using a Rare Event Imaging System Stine-Kathrein Kraeft, Ravi Salgia, and Lan Bo Chen	423
27	Reconstruction of Geno-Phenotypic Evolutionary Sequences from Intracellular Patterns of Molecular Abnormalities in Human Solid Tumors Stanley E. Shackney, Charles A. Smith, Agnese A. Pollice, and Jan F. Silverman	431
PART III. NOVEL THERAPIES		
A. INTRODUCTION TO CURRENT TREATMENTS		
28	Surgical Treatment of Lung Cancer: <i>Past and Present</i> Clifton F. Mountain and Kay E. Hermes	453

29	Recent Advances and Dilemmas in the Radiotherapeutic Management of Locally Advanced Non-Small Cell Lung Cancer Benjamin Movsas	489
30	Photodynamic Therapy in Lung Cancer: A Review David Ost	507
B. GENE THERAPIES		
	<i>I. Overview: Advantages and Pitfalls of Lung-Targeted Gene Therapies</i>	
31	Gene Therapy for Lung Cancer: An Introduction Eric B. Haura, Eduardo Sotomayor, and Scott J. Antonia	529
32	Identifying Obstacles to Viral Gene Therapy for Lung Cancer: <i>Malignant Pleural Effusions as a Paradigm</i> Raj K. Batra, Raymond M. Bernal, and Sherven Sharma	545
33	Topical Gene Therapy for Pulmonary Diseases with PEI-DNA Aerosol Complexes Ajay Gautam, J. Clifford Waldrep, Frank M. Orson, Berma M. Kinsey, Bo Xu, and Charles L. Densmore	561
	<i>II. Plasmid and Virus-Based Gene Therapies</i>	
34	Targeted Delivery of Expression Plasmids to the Lung via Macroaggregated Polyethylenimine-Albumin Conjugates Frank M. Orson, Berma M. Kinsey, Balbir S. Bhogal, Ling Song, Charles L. Densmore, and Michael A. Barry	575
35	Preparation of Retroviral Vectors for Cell-Cycle-Targeted Gene Therapy of Lung Cancer Pier Paolo Claudio and Antonio Giordano	591
36	Aerosol Gene Therapy for Metastatic Lung Cancer Using PEI-p53 Complexes Ajay Gautam, J. Clifford Waldrep, Eugenie S. Kleinerman, Bo Xu, Yuen-Kai Fung, Anne T'Ang, and Charles L. Densmore	607
	<i>III. Antisense Oligonucleotide Gene Therapies</i>	
37	Clinical Development of Antisense Oligonucleotides as Anti-Cancer Therapeutics Helen X. Chen	621
38	Antisense Oligonucleotides Targeting R1 α Subunit of Protein Kinase A: <i>In Vitro and In Vivo Anti-Tumor Activity and Pharmacokinetics</i> Ruiwen Zhang and Hui Wang	637

39	Use of Antisense Oligonucleotides for Therapy: <i>Manipulation of Apoptosis Inhibitors for Destruction of Lung Cancer Cells</i> Siân H. Leech, Robert A. Olie, and Uwe Zangemeister-Wittke	655
40	Induction of Programmed Cell Death with an Antisense Bcl-2 Oligonucleotide Patrick P. Koty, Wendong Lei, and Mark L. Levitt	671
<i>C. IMMUNE THERAPIES</i>		
41	Tumor Vaccination with Cytokine-Encapsulated Microspheres Nejat K. Egilmez, Yong S. Jong, Edith Mathiowitz, and Richard B. Bankert	687
42	Adoptive Immunotherapy Julian A. Kim and Suyu Shu	697
43	Intratumoral Therapy with Cytokine Gene-Modified Dendritic Cells in Murine Lung Cancer Models Sherven Sharma, Seok Chul Yang, Raj K. Batra, and Steven M. Dubinett	711
44	Cyclooxygenase 2-Dependent Regulation of Antitumor Immunity in Lung Cancer Sherven Sharma, Min Huang, Mariam Dohadwala, Mehdi Pold, Raj K. Batra, and Steven M. Dubinett	723
<i>D. CHEMOPREVENTION</i>		
45	Chemoprevention of Lung Cancer Hanspeter Witschi	739
46	Assessing the Interaction of Particulate Delivery Systems with Lung Surfactant Timothy Scott Wiedmann	755
47	Chemopreventive Therapeutics: <i>Inhalation Therapies for Lung Cancer and Bronchial Premalignancy</i> Missak Haigentz, Jr. and Roman Perez-Soler	771
	Index	781

Lung Cancer

Volume 2: Diagnostic and Therapeutic Methods and
Reviews

Driscoll, B. (Ed.)

2003, XXIII, 816 p., Hardcover

ISBN: 978-0-89603-920-9

A product of Humana Press